NCT05359484

Brief Summary

To determine the significance of delta Q value (Qmax - Qave) in discrimination between BOO and DU, to avoid invasive studies (pressure flow studies (PFSs)) and replace them with noninvasive study (uroflowmetry).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
238

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jan 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2019

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2021

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2021

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

April 23, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 3, 2022

Completed
Last Updated

May 3, 2022

Status Verified

April 1, 2022

Enrollment Period

2 years

First QC Date

April 23, 2022

Last Update Submit

April 29, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Q average

    Q average it represents the difference between Qmax and Q average in ml/sec as shown in uroflowmetry

    preoperative test, it is done only once and comparative evaluation with other parameters will be done

Secondary Outcomes (3)

  • Q max

    preoperative test, it is done only once and comparative evaluation with other parameters will be done

  • Q Average

    preoperative test, it is done only once and comparative evaluation with other parameters will be done

  • post voiding residual urine

    preoperative test, it is done only once and comparative evaluation with other parameters will be done

Study Arms (2)

detrusor underactivity

EXPERIMENTAL

according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post void residual urine (PVR), and value of Qmax minus Qave (DeltaQ) were obtained.

Diagnostic Test: Uroflowmetry

bladder out flow obstruction

EXPERIMENTAL

according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post void residual urine (PVR), and value of Qmax minus Qave (DeltaQ) were obtained.

Diagnostic Test: Uroflowmetry

Interventions

UroflowmetryDIAGNOSTIC_TEST

according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post-void residual urine (PVR), and value of Qmax minus Qaverage (DeltaQ) were obtained.

bladder out flow obstructiondetrusor underactivity

Eligibility Criteria

Age50 Years+
Sexmale(Gender-based eligibility)
Gender Eligibility Detailsthe main part of the bladder outlet obstruction is caused by the prostate that is why this study is based in male population
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • male patients aged over 50 years complaining of voiding symptoms
  • International Prostatic Symptom Score (IPSS) 8 points or more,
  • serum prostate-specific antigen (PSA) below 4 ng/ml
  • no hematuria or pyuria.

You may not qualify if:

  • Patients who were unable to complete the voiding study were deemed not eligible to participate in this review.
  • patients with neurological causes of voiding dysfunction
  • history of urinary tract abnormalities/lithiasis, lower urinary tract surgeries, urinary tract malignancy.
  • acute UTI were excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ahmed Maher

Cairo, Cairo Governorate, 11757, Egypt

Location

MeSH Terms

Conditions

Urinary Bladder, Underactive

Condition Hierarchy (Ancestors)

Urinary Bladder DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Model Details: Usage of Uroflowmetry to distinguish between bladder outlet obstruction and detrusor hypo-contractility
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principle investigator

Study Record Dates

First Submitted

April 23, 2022

First Posted

May 3, 2022

Study Start

January 1, 2019

Primary Completion

January 1, 2021

Study Completion

May 1, 2021

Last Updated

May 3, 2022

Record last verified: 2022-04

Locations